PMID: 6983519Nov 1, 1982Paper

Selective reactivity of sera from alloimmunized sheep and cattle against human T and leukemia cells

Human Immunology
J HorsM Bernoco

Abstract

Human B and T lymphocytes from a panel of healthy individuals were tested against serial dilutions of 68 mare, 81 cow, 7 sow, and 87 ewe sera. All the animals had been alloimmunized by pregnancies and/or blood transfusions. Weak correlations with HLA-A, B, C, and DR specificities were found in 20 sera. Twelve other sera, 9 from ewes and 3 from cows, had a strong reactivity against T lymphocytes but weak or no reactivity against B cells, spleen null cells, granulocytes, and platelets, suggesting a non-major histocompatibility complex (MHC) cross-reactivity. They were cytotoxic for most of the cells of malignant proliferative origin tested thus far, including T acute lymphoblastic leukemia (T ALL), common ALL (cALL), acute myeloblastic leukemia (AML), and Sezary cells, but were negative with B lymphoblastoid cell lines and cells from patients with B chronic lymphocytic leukemia (CLL) and chronic myelocytic leukemia (CML). The hypothesis that humans and certain other mammals share a common determinant on T-lineage cells and some malignant cells is advanced.

References

Jan 1, 1981·The Journal of Experimental Medicine·M KamounR C Nowinski
Oct 1, 1981·Human Immunology·F M BrodskyP Parham
May 1, 1982·Transplantation·J C CicciarelliR Billing
Dec 5, 1964·Nature·P I TERASAKI, J D MCCLELLAND

❮ Previous
Next ❯

Citations

Jan 1, 1984·Developmental and Comparative Immunology·D A Higgins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

The Australian Journal of Experimental Biology and Medical Science
J J Morrison, W J Halliday
Developmental and Comparative Immunology
D A HigginsC Richardson
Veterinary Immunology and Immunopathology
V K Kuchroo, P A Jennings
© 2021 Meta ULC. All rights reserved